These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12454566)

  • 41. Clozapine augmented with aripiprazole in 5 patients with schizophrenia.
    Abu-Tair F; Kopitz J; Bergemann N
    J Clin Psychopharmacol; 2006 Dec; 26(6):669-71. PubMed ID: 17110831
    [No Abstract]   [Full Text] [Related]  

  • 42. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers.
    Wang CY; Zhang ZJ; Li WB; Zhai YM; Cai ZJ; Weng YZ; Zhu RH; Zhao JP; Zhou HH
    J Clin Pharmacol; 2004 Jul; 44(7):785-92. PubMed ID: 15199083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels.
    Wehring HJ; Elsobky T; McEvoy JP; Vyas G; Richardson CM; McMahon RP; DiPaula BA; Liu F; Sullivan K; Buchanan RW; Feldman S; McMahon EM; Kelly DL
    Psychiatr Q; 2018 Mar; 89(1):73-80. PubMed ID: 28466366
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of amisulpride augmentation of clozapine in a non-responder to either drug alone: a case report.
    George S; Cowan C
    Acta Psychiatr Scand; 2005 Feb; 111(2):163. PubMed ID: 15667440
    [No Abstract]   [Full Text] [Related]  

  • 45. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine.
    Szegedi A; Wiesner J; Hiemke C
    J Clin Psychopharmacol; 1995 Apr; 15(2):141-3. PubMed ID: 7782489
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
    Rajkumar AP; Poonkuzhali B; Kuruvilla A; Jacob M; Jacob KS
    Int Clin Psychopharmacol; 2013 Jan; 28(1):50-6. PubMed ID: 23104241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Case report: Pharmacokinetic interaction between clozapine and mirtazapine.
    Lo Presti C; Laguin S; Bambina E; Arlotto E; Aghazarian V; Guise-Honore S
    Encephale; 2019 Sep; 45(4):363-364. PubMed ID: 30879778
    [No Abstract]   [Full Text] [Related]  

  • 48. Serum level of clozapine and relapse.
    Ulrich S; Wolf R; Staedt J
    Ther Drug Monit; 2003 Apr; 25(2):252-5. PubMed ID: 12657924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia.
    Zink M; Mase E; Dressing H
    Hum Psychopharmacol; 2004 Jun; 19(4):271-3. PubMed ID: 15181656
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations.
    Augustin M; Schoretsanitis G; Pfeifer P; Gründer G; Liebe C; Paulzen M
    Schizophr Res; 2019 Aug; 210():143-148. PubMed ID: 31182321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Addition of risperidone to clozapine therapy in chronically psychotic inpatients.
    de Groot IW; Heck AH; van Harten PN
    J Clin Psychiatry; 2001 Feb; 62(2):129-30. PubMed ID: 11247102
    [No Abstract]   [Full Text] [Related]  

  • 52. Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis.
    Veerman SR; Schulte PF; Begemann MJ; de Haan L
    Pharmacopsychiatry; 2014 Nov; 47(7):231-8. PubMed ID: 25121994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Augmenting atypical antipsychotic medications with clozapin].
    Zink M; Dressing H
    Nervenarzt; 2005 Sep; 76(9):1092, 1094-8, 1100-2. PubMed ID: 15782324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Weight Loss During Atomoxetine Add-on to Clozapine-Responsive Schizophrenia.
    Naguy A; Alamiri B; Khraibut B
    Am J Ther; 2018; 25(6):e774-e775. PubMed ID: 29782344
    [No Abstract]   [Full Text] [Related]  

  • 55. Evaluation of anti-colitic effect of fluvoxamine against acetic acid-induced colitis in normal and reserpinized depressed rats.
    Minaiyan M; Hajhashemi V; Rabbani M; Fattahian E; Mahzouni P
    Eur J Pharmacol; 2015 Jan; 746():293-300. PubMed ID: 25460023
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Letter to the editor: reply to Legare et al.
    van Westrhenen R; Schulte PF; Sommer I
    Med Hypotheses; 2014 Sep; 83(3):418. PubMed ID: 25012779
    [No Abstract]   [Full Text] [Related]  

  • 57. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
    Reznik I; Sirota P
    J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fluvoxamine-clozapine dose-dependent interaction.
    Markowitz JS; Gill HS; Lavia M; Brewerton TD; DeVane CL
    Can J Psychiatry; 1996 Dec; 41(10):670-1. PubMed ID: 8978949
    [No Abstract]   [Full Text] [Related]  

  • 59. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.
    Spina E; Avenoso A; Facciolà G; Fabrazzo M; Monteleone P; Maj M; Perucca E; Caputi AP
    Int Clin Psychopharmacol; 1998 May; 13(3):141-5. PubMed ID: 9690983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa.
    Ikenouchi-Sugita A; Yoshimura R; Hori H; Ueda N; Nakamura J
    Psychiatry Clin Neurosci; 2007 Aug; 61(4):452. PubMed ID: 17610677
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.